Royal Bank Of Canada Increases Gilead Sciences (NASDAQ:GILD) Price Target to $105.00

Gilead Sciences (NASDAQ:GILD) had its price objective lifted by Royal Bank Of Canada from $100.00 to $105.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price suggests a potential downside of 12.35% from the stock’s current price.

A number of other analysts also recently weighed in on GILD. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Cantor Fitzgerald restated an “overweight” rating and issued a $135.00 price objective on shares of Gilead Sciences in a research note on Friday. Rothschild & Co Redburn increased their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective for the company in a research note on Tuesday, August 19th. Finally, Wells Fargo & Company increased their price objective on shares of Gilead Sciences from $140.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $123.87.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $119.79 on Friday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences has a fifty-two week low of $86.08 and a fifty-two week high of $124.61. The firm has a fifty day moving average price of $115.66 and a two-hundred day moving average price of $111.61. The company has a market cap of $148.64 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 0.81 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same period in the prior year, the firm earned $2.02 EPS. The business’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts expect that Gilead Sciences will post 7.95 EPS for the current year.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the sale, the chief financial officer owned 157,055 shares in the company, valued at $18,545,054.40. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $354,240.00. Following the sale, the insider owned 110,193 shares of the company’s stock, valued at $13,011,589.44. This trade represents a 2.65% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 71,500 shares of company stock worth $8,336,040 in the last quarter. 0.27% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Gilead Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Activest Wealth Management increased its position in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. GoalVest Advisory LLC increased its position in Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. Corundum Trust Company INC acquired a new stake in Gilead Sciences in the 3rd quarter valued at about $26,000. Harbor Asset Planning Inc. acquired a new stake in Gilead Sciences in the 2nd quarter valued at about $27,000. Finally, Putney Financial Group LLC increased its position in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.